BiondVax Pharmaceuticals Ltd (NASDAQ:BVXV)
| 3.21 Delayed Data As of 3:49pm ET |  +0.02 / +0.63%Today’s Change | 2.35 Today|||52-Week Range 62.00 | -65.45% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $37.9M |
Company Description
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. It works on M-001, a synthetic peptide-based protein targeting both seasonal and pandemic strains of the influenza virus. The company was founded by Ron Babecoff and Rami Epstein on July 22, 2003 and is headquartered in Jerusalem, Israel.
Contact Information
BiondVax Pharmaceuticals Ltd. Jerusalem BioPark Jerusalem Jerusalem 74036 |
Employees
Shareholders
| Other institutional | 0.91% |
| Mutual fund holders | 0.43% |
| Individual stakeholders | -- |
Top Executives
| Ronald Babecoff | President, Chief Executive Officer & Director |
| Elad Mark | Chief Operating Officer |
| Uri Ben-Or | Chief Financial Officer |
| Tamar Ben-Yedidia | Chief Scientific Officer |
| Shai Ashkenazi | Medical Director |
